Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THYROPED: Hypothyroidism Risk with Iodinated Contrast Media
NCT03631771Phase 4Withdrawn
- Sponsor
- GE HealthCare
- Start
- Mar 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of iohexol, iodixanol, iopromide and ioversol, sponsored by GE HealthCare. Primary endpoint: Proportion of subjects who develop hypothyroidism post-ICM at 6 months. Planned start Mar 2022; status: withdrawn.
02
Drugs
iohexoliodixanoliopromideioversol
Beyond the preview
Go deeper on NCT03631771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631771.